Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02266160
Other study ID # 0055-14
Secondary ID
Status Completed
Phase Phase 4
First received September 22, 2014
Last updated February 27, 2018
Start date November 2014
Est. completion date December 2015

Study information

Verified date February 2018
Source HaEmek Medical Center, Israel
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The investigators like to learn whether EMLA cream 5% helps tinnitus patients. so far it is known that lidocaine I.V do helps tinnitus but until now it is not clear if topical anaesthetics (e.g EMLA cream) helps tinnitus.

The investigators are going to compare 4 days of treatment of EMLA 5% cream Versus (VS.) cetomacrogol cream (water- based lotion cream) in treating tinnitus patients.


Description:

The purpose of the study is to investigate whether EMLA 5% cream decreases tinnitus by comparing pretrial questionnaires to post trial questionnaires.

first we are going to invite tinnitus patients for the first visit. in the first visit we will confirm that the patients is suitable for the trial (no exclusion criteria are present) , perform ear investigation to exclude ear inflammation, perform audiometry to prove sensorineural hearing loss. then the patient will fill 3 questionnaires that reflect the tinnitus severity and show how much the patient does suffer from this conditions. the questionnaires are- beck depression index, tinnitus handicap inventory, Pittsburgh sleep quality index.

Then we will perform randomization: the investigational group will get EMLA 5% cream, the control group will get cetomacrogol cream (a lotion cream).

In the next 4 days the patients (investigational and control groups) will spread the cream for 4 hours a day in the post auricular area of the ear/ ears that suffer/s from tinnitus.

The patient will be instructed to stop the spreading and call the chief investigator When any kind of side effect occurs (topical/ systemic)after 4 days of treatment the patient will come to the clinic once again and fill the same questionnaires. 3 weeks after the beginning of the trial the patient will fill the questionnaires for the third time.

Regarding the questionnaires:

1. Beck depression questionnaire is a 21-questions exam that checks the depression level of the patient. The minimum score is 1 the maximum is 63. The investigators hypotheses states that EMLA cream treatment decreases the Beck questionnaire score

2. Pittsburgh sleep quality index is a 9 questions exam that measure the quality of sleep. the range of results goes between 0-24. The higher the score- the worse is the quality of sleep. The investigators hypotheses states that EMLA treatment improves the results of the Pittsburgh sleep quality questionnaires.

3. Tinnitus handicap inventory estimates the degree that tinnitus affects patients life. it contains 25 questions . The minimum score is 0 and the maximum is 100 . The investigators hypotheses that EMLA cream treatment decreases the score of this questionnaire which means that EMLA cream improves patients quality of life.


Recruitment information / eligibility

Status Completed
Enrollment 142
Est. completion date December 2015
Est. primary completion date November 2015
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- mature (above 18 years old) patients that suffer tinnitus (unilateral/bilateral) with sensorineural hearing loss

Exclusion Criteria:

- patients that are treated for tinnitus( psychological treatment, hearing aid)

- drugs that affect the CNS

- sensitivity to amide anaesthetic

- hepatic failure

- usage of antiarrhythmic drugs

- severe depression any patients that develops during the trial local/ systemic symptoms such as rash, pain, itching, fever, nervousness,palpitations will be omitted from the study

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
EMLA cream 5%
the interventional group will spread 2 grams (2 m"l) of EMLA cream over the post auricular area. after 4 hours the patient will wash away the cream. the treatment will last 4 days.
Other:
cetomacrogol cream (lotion cream)
lotion cream that does not contain active drug. has no contraindications

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
HaEmek Medical Center, Israel

Outcome

Type Measure Description Time frame Safety issue
Primary questionnaire results- Beck depression questionnaire Beck depression questionnaire: A 21- questions exam that checks the depression level of the patient. the minimum score is 1 and the maximum score is 63. The investigators hypotheses states that EMLA cream treatment decreases the Beck questionnaire score after 4 days of treatment
Primary questionnaire results- Pittsburgh sleep quality index Pittsburgh sleep quality index : A 9 questions exam that measure the quality of sleep. The range of results goes between 0-24. The higher the score - the worse is the quality of sleep. The investigators hypotheses states that EMLA treatment improves the results of Pittsburgh sleep quality index after 4 days of treatment
Primary questionnaire results- tinnitus handicap inventory tinnitus handicap inventory: estimates the degree that tinnitus affects patients life. It contains 25 questions. The minimum score is 0 and the maximum is 100. The investigators hypotheses that EMLA cream treatment decreases the score of this questionnaire which means that EMLA cream improves patients quality of life after 4 days of treatment
Secondary questionnaire results - Beck depression questionnaire estimation of this questionnaire after 2 weeks of treatment 2 weeks after the beginning of treatment
Secondary questionnaire results- Pittsburgh sleep quality index estimation of this questionnaire after 2 weeks of treatment 2 weeks after the beginning of treatment
Secondary questionnaire results- tinnitus handicap inventory estimation of this questionnaire after 2 weeks of treatment 2 weeks after the beginning of treatment
See also
  Status Clinical Trial Phase
Recruiting NCT05963542 - Efficacy of Online Acceptance and Commitment Therapy and Sound Therapy for Patients With Tinnitus and Insomnia N/A
Recruiting NCT04987502 - Virtual Reality and Subjective Tinnitus N/A
Recruiting NCT04404439 - Treatment of Tinnitus With Migraine Medications Phase 4
Recruiting NCT05533840 - Establishment and Application of a New Imaging System for Otology Based on Ultra-high Resolution CT
Completed NCT03552302 - Effects of Yoga Exercise on Participates With Tinnitus
Enrolling by invitation NCT02617953 - Objective Diagnosis Method and Efficacy of Repetitive Transcranial Magnetic Stimulation as a Treatment for Tinnitus N/A
Completed NCT02974543 - Somatosensory Stimulation to Alleviate Tinnitus N/A
Completed NCT02269839 - A Feasibility Study Assessing the Effectiveness of rTMS in Tinnitus N/A
Withdrawn NCT01663467 - Efficacy of Internet and Smartphone Application-delivered Tinnitus Retraining Therapy N/A
Completed NCT01929837 - Tinnitus rTMS 2013 N/A
Completed NCT01857661 - The Influence of the Sound Generator Combined With Conventional Amplification for Tinnitus Control: Blind Randomized Clinical Trial N/A
Completed NCT01927991 - Internet-based Self-help for Tinnitus: The Role of Support N/A
Completed NCT01480193 - New Therapy for Patients With Severe Tinnitus N/A
Terminated NCT01412918 - Inhibitor Masking Device & Sodium Channel, Voltage Gated, Type IX Alpha Subunit (SCN9) Gene Expression N/A
Completed NCT00371436 - Progressive Intervention Program for Tinnitus Management N/A
Completed NCT00748475 - Countering Stimulus-Induced Alpha-Desynchronization to Treat Tinnitus N/A
Completed NCT00733044 - Cost-effectiveness of Multidisciplinary Management of Tinnitus N/A
Active, not recruiting NCT05518682 - Assessment of Bimodal Stimulation Device Compliance and Satisfaction in Individuals With Tinnitus N/A
Recruiting NCT05212298 - Effects of Herbal Sleep Formula on Patients With Insomnia and Tinnitus N/A
Completed NCT06025097 - Intra-Tympanic Steroid With PRP Combination in Sensorineural Hearing Loss and Tinnitus. Early Phase 1